Burlingame, Calif.-based Inflammatix develops a molecular diagnostic designed to read the patient’s immune system to deliver rapid results, with an initial focus on acute infection and sepsis. Its HostDx tests combine proprietary biomarkers and advanced machine learning. The company was included on Medical Design & Outsourcing’s list of 20 startups you need to know.
Tests developed by Inflammatix can identify the presence and type of infection and the risk of severe disease to enable more informed decisions by physicians. The tests are run on the company’s sample-to-answer, cartridge-based, point-of-care Myrna test system designed to deliver results in under 30 minutes.
Funds raised in the Series D are earmarked to support regulatory clearance and global commercialization of the Myrna sy…